Blood markers of oxidative stress in Alzheimer's disease
Language English Country England, Great Britain Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
F32 NS010331
NINDS NIH HHS - United States
PubMed
22564475
PubMed Central
PMC3823422
DOI
10.1111/j.1582-4934.2012.01585.x
Knihovny.cz E-resources
- MeSH
- Alzheimer Disease blood diagnosis physiopathology MeSH
- Antioxidants analysis MeSH
- Biomarkers blood MeSH
- Humans MeSH
- Brain metabolism physiopathology MeSH
- Nucleic Acids metabolism MeSH
- Oxidative Stress * MeSH
- Lipid Peroxidation MeSH
- Proteins metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antioxidants MeSH
- Biomarkers MeSH
- Nucleic Acids MeSH
- Proteins MeSH
Alzheimer's disease (AD) represents a highly common form of dementia, but can be diagnosed in the earlier stages before dementia onset. Early diagnosis is crucial for successful therapeutic intervention. The introduction of new diagnostic biomarkers for AD is aimed at detecting underlying brain pathology. These biomarkers reflect structural or biochemical changes related to AD. Examination of cerebrospinal fluid has many drawbacks; therefore, the search for sensitive and specific blood markers is ongoing. Investigation is mainly focused on upstream processes, among which oxidative stress in the brain is of particular interest. Products of oxidative stress may diffuse into the blood and evaluating them can contribute to diagnosis of AD. However, results of blood oxidative stress markers are not consistent among various studies, as documented in this review. To find a specific biochemical marker for AD, we should concentrate on specific metabolic products formed in the brain. Specific fluorescent intermediates of brain lipid peroxidation may represent such candidates as the composition of brain phospholipids is unique. They are small lipophilic molecules and can diffuse into the blood stream, where they can then be detected. We propose that these fluorescent products are potential candidates for blood biomarkers of AD.
See more in PubMed
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–44. PubMed
Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22:2314–24. PubMed
Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition. Stroke. 2011;42:2651–65. PubMed
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–9. PubMed PMC
Hort J, O'Brien JT, Gainotti G, et al. On Behalf of the EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17:1236–48. PubMed
Hort J, Glosová L, Vyhnálek M, et al. The liquor tau protein and beta amyloid in Alzheimer's disease. Ces Slov Neurol Neurochir. 2007;70:30–6.
Maruta C, Guerreiro M, de Mendonça A, et al. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol. 2011;18:279–85. PubMed
Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32:20–36. PubMed PMC
Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging. 2002;23:485–508. PubMed
Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med. 2010;16:1218–22. PubMed
Bonda DJ, Wang X, Perry G, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology. 2010;59:290–4. PubMed
Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging. 2009;30:337–52. PubMed
Popescu BO, Toescu EC, Popescu LM, et al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci. 2009;283:99–106. PubMed
Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011;17:1060–5. PubMed
Shimohama S, Tanino H, Kawakami N, et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun. 2000;273:5–9. PubMed
Cagnin A, Brooks DJ, Kennedy AM, et al. In vivo measurement of activated microglia in dementia. Lancet. 2001;358:461–7. PubMed
Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's β-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol. 2000;130:184–208. PubMed
Lynch T, Herny RA, Bush AI. Oxidative processes in Alzheimer's disease: the role of Aβ-metal interactions. Exp Gerontol. 2000;35:445–51. PubMed
Cornet CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicity. 1998;19:339–45. PubMed
Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:759–67. PubMed
Nunomura A, Perry G, Pappolla MA, et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol. 2000;59:1011–7. PubMed
Odetti P, Angelini G, Dapino D, et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun. 1998;243:849–51. PubMed
Pratico D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001;21:4183–7. PubMed PMC
Söderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer disease. Lipids. 1991;26:421–5. PubMed
Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 1995;45:1594–601. PubMed
Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. 1998;19:33–6. PubMed
Keller JN, Schmitt FA, Scheff SW, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005;7:1152–6. PubMed
Butterfield DA, Reed T, Perluigi M, et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett. 2006;3:170–3. PubMed
Montine TJ, Quinn J, Kaye J, Morrow JD. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci. 2007;33:114–9. PubMed
Praticò D, Clark CM, Lee VM, et al. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol. 2000;48:809–12. PubMed
Montine TJ, Markesbery WR, Morrow JD, Roberts LJ., II Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol. 1998;44:410–3. PubMed
Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol. 2005;5:730–5. PubMed
Roberts LJ, II, Montine TJ, Markesbery WR, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem. 1998;273:13605–12. PubMed
Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J. 2002;43:28–32. PubMed
Polidori MC, Mecocci P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis. 2002;4:517–22. PubMed
Aybek H, Ercan F, Aslan D, Sahiner T. Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey. Clin Biochem. 2007;40:172–6. PubMed
Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, et al. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing. 2001;30:235–41. PubMed
Greilberger J, Koidl C, Greilberger M, et al. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res. 2008;42:633–8. PubMed
Casado A, Encarnación López-Fernández M, Concepción Casado M, de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res. 2008;33:450–8. PubMed
Martín-Aragón S, Bermejo-Bescós P, Benedí J, et al. Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochem Res. 2009;34:373–8. PubMed
Cecchi C, Fiorillo C, Sorbi S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med. 2002;15:1372–9. PubMed
Sinem F, Dildar K, Gökhan E, et al. The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res. 2010;7:463–9. PubMed
Serra JA, Domínguez RO, Marschoff ER, et al. Systemic oxidative stress associated with the neurological diseases of aging. Neurochem Res. 2009;34:2122–32. PubMed
Serra JA, Domínguez RO, de Lustig ES, et al. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J Neural Transm. 2001;108:1135–48. PubMed
Kawamoto EM, Munhoz CD, Glezer I, et al. Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease. Neurobiol Aging. 2005;26:857–64. PubMed
Ahlskog JE, Uitti RJ, Low PA, et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord. 1995;10:566–73. PubMed
Ceballos-Picot I, Merad-Boudia M, Nicole A, et al. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type–place of the extracellular glutathione peroxidase. Free Radic Biol Med. 1996;20:579–87. PubMed
Fernandes MA, Proenca MT, Nogueira AJ, et al. Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int J Mol Med. 1999;4:179–86. PubMed
Sinclair AJ, Bayer AJ, Johnston J, et al. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry. 1998;13:840–5. PubMed
McGrath LT, McGleenon BM, Brennan S, et al. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM. 2001;94:485–90. PubMed
Polidori MC, Mattioli P, Aldred S, et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord. 2004;18:265–70. PubMed
Selley ML, Close DR, Stern SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging. 2002;23:383–8. PubMed
Calabrese V, Sultana R, Scapagnini G, et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal. 2006;8:1975–86. PubMed
Praticò D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972–6. PubMed
Irizarry MC, Yao Y, Hyman BT, et al. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis. 2007;4:403–5. PubMed
Feillet-Coudray C, Tourtauchaux R, Niculescu M, et al. Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med. 1999;27:463–9. PubMed
Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 2002;52:175–9. PubMed
Sundelöf J, Kilander L, Helmersson J, et al. Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis. 2009;18:71–8. PubMed
Hensley K, Hall N, Subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem. 1995;65:2146–56. PubMed
Ahmed N, Ahmed U, Thornalley PJ, et al. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem. 2005;92:255–63. PubMed
Butterfield DA, Reed TT, Perluigi M, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 2007;1148:243–8. PubMed PMC
Greilberger J, Fuchs D, Leblhuber F, et al. Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation. Clin Lab. 2010;56:441–8. PubMed
Bermejo P, Martín-Aragón S, Benedí J, et al. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Free Radic Res. 2008;42:162–70. PubMed
Conrad CC, Marshall PL, Talent JM, et al. Oxidized proteins in Alzheimer's plasma. Biochem Biophys Res Commun. 2000;275:678–81. PubMed
Aldred S, Bennett S, Mecocci P. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clin Biochem. 2010;43:267–71. PubMed
Yu HL, Chertkow HM, Bergman H, Schipper HM. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics. 2003;3:2240–8. PubMed
Choi J, Malakowsky CA, Talent JM, et al. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun. 2002;293:1566–70. PubMed
Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 1994;36:747–51. PubMed
Nunomura A, Perry G, Pappolla MA, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci. 1999;19:1959–64. PubMed PMC
Mullaart E, Boerrigter ME, Ravid R, et al. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging. 1990;11:169–73. PubMed
Mecocci P, Polidori MC, Ingegni T, et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology. 1998;51:1014–7. PubMed
Mecocci P, Polidori MC, Cherubini A, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol. 2002;59:794–8. PubMed
Mórocz M, Kálmán J, Juhász A, et al. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging. 2002;23:47–53. PubMed
Kadioglu E, Sardas S, Aslan S, et al. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers. 2004;9:203–9. PubMed
Migliore L, Fontana I, Trippi F, et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging. 2005;26:567–73. PubMed
Abe T, Tohgi H, Isobe C, et al. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res. 2002;70:447–50. PubMed
Foy CJ, Passmore AP, Vahidassr MD, et al. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM. 1999;92:39–45. PubMed
Jeandel C, Nicolas MB, Dubois F, et al. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology. 1989;35:275–82. PubMed
Rivière S, Birlouez-Aragon I, Nourhashémi F, Vellas B. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry. 1998;13:749–54. PubMed
Zaman Z, Roche S, Fielde P, et al. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing. 1992;21:91–4. PubMed
Jiménez-Jiménez FJ, de Bustos F, Molina JA, et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J Neural Transm. 1997;104:703–10. PubMed
Paraskevas GP, Kapaki E, Libitaki G, et al. Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol Scand. 1997;96:88–90. PubMed
Repetto MG, Reides CG, Evelson P, et al. Peripheral markers of oxidative stress in probable Alzheimer patients. Eur J Clin Invest. 1999;29:643–9. PubMed
Guidi I, Galimberti D, Lonati S, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006;27:262–9. PubMed
Grünblatt E, Schlösser R, Fischer P, et al. Oxidative stress related markers in the “VITA” and the centenarian projects. Neurobiol Aging. 2005;26:429–38. PubMed
Long EK, Picklo MJ., Sr Trans-4-hydroxy-2-hexenal, a product of n-3 fatty acid peroxidation: make some room HNE. Free Radic Biol Med. 2010;49:1–8. PubMed
Wilhelm J, Brzak P, Rejholcova M. Changes of lipofuscin-like pigments in erythrocytes and spleen after whole-body gamma irradiation of rats. Radiat Res. 1989;120:227–33. PubMed
Skoumalová A, Rofina J, Schwippelová Z, et al. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol. 2003;38:711–9. PubMed
Skoumalová A, Ivica J, Šantorová P, et al. The lipid peroxidation products as possible markers of Alzheimer's disease in blood. Exp Gerontol. 2011;46:38–42. PubMed
Analysis of lipophilic fluorescent products in blood of Alzheimer's disease patients